BioCardia Announced A Long-term Partnership To Advance StemCardia's Investigational Pluripotent Stem Cell Product Candidate For The Treatment Of Heart Failure
BioCardia Announced A Long-term Partnership To Advance StemCardia's Investigational Pluripotent Stem Cell Product Candidate For The Treatment Of Heart Failure
BioCardia宣布建立长期合作伙伴关系，以推进Stemcardia在研的用于治疗心力衰竭的多能干细胞候选产品
Under the partnership, BioCardia is the exclusive biotherapeutic delivery partner for StemCardia's cell therapy candidate through studies expected to result in FDA approval of an investigational new drug application (IND) and the anticipated Phase I/II clinical development to follow.
根据该合作伙伴关系，BioCardia是Stemcardia候选细胞疗法的独家生物治疗交付合作伙伴，其研究预计将导致FDA批准一项在研新药申请（IND），预计随后将进行I/II期临床开发。